Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Faculty of Infectious and Tropical Diseases, Disease Control Department, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Trials. 2024 Feb 28;25(1):151. doi: 10.1186/s13063-024-07969-2.
The massive scale-up of long-lasting insecticidal nets (LLIN) has led to a major reduction in malaria burden in many sub-Saharan African (SSA) countries. The World Health Organization (WHO) has recently issued a strong recommendation for the use of chlorfenapyr-pyrethroid LLINs compared to standard pyrethroid-only LLINs in areas of high insecticide resistance intensity. However, there is still a lack of conclusive evidence on the efficacy of piperonyl butoxide-pyrethroid (PBO-py) LLINs, especially in West Africa, where vector composition and resistance mechanisms may be different from vectors in East Africa.
This is a three-arm, superiority, triple-blinded, cluster randomised trial, with village as the unit of randomisation. This study conducted in Côte d'Ivoire will evaluate the efficacy on epidemiological and entomological outcomes of (1) the control arm: MAGNet® LN, which contains the pyrethroid, alpha-cypermethrin, (2) VEERALIN® LN, a net combining the synergist PBO and alpha-cypermethrin, and (3) Interceptor® G2 LN, which incorporates chlorfenapyr and alpha-cypermethrin, two adulticides with different mechanisms of action. A total of 33 villages with an average of 200 households per village will be identified, mapped, and randomised in a ratio of 1:1:1. Nets will be distributed at a central point following national guidelines with 1 net for every 2 people. The primary outcome of the trial will be incidence of malaria cases (confirmed by rapid diagnostic test (RDT)) in a cohort of 50 children aged 6 months to 10 years in each cluster, followed for 12 months (active case detection). Secondary outcomes are cross-sectional community prevalence of malaria infection (confirmed by RDT) in the study population at 6 and 12 months post-intervention (50 randomly selected persons per cluster), vector density, entomological inoculation rate (EIR), and phenotypic and genotypic insecticide resistance at baseline and 12 months post-intervention in 3 sentinel villages in each treatment arm.
In addition to generating further evidence for next-generation LLINs, this study will also provide the first evidence for pyrethroid-PBO nets in a West African setting. This could further inform WHO recommendations on the pragmatic use of pyrethroid-PBO nets.
ClinicalTrials.gov NCT05796193. Registered on April 3, 2023.
长效杀虫蚊帐(LLIN)的大规模推广已导致许多撒哈拉以南非洲(SSA)国家的疟疾负担大幅减轻。世界卫生组织(WHO)最近强烈建议在抗药性强度高的地区使用氯氟氰菊酯-拟除虫菊酯 LLIN,而不是标准的仅含拟除虫菊酯的 LLIN。然而,关于增效醚-拟除虫菊酯(PBO-拟除虫菊酯)LLIN 的疗效仍缺乏确凿的证据,特别是在西非,那里的蚊虫组成和抗药性机制可能与东非不同。
这是一项三臂、优效性、三盲、整群随机试验,以村庄为随机单位。这项在科特迪瓦进行的研究将评估(1)对照臂:MAGNet® LN,含有拟除虫菊酯,alpha-氯氰菊酯;(2)VEERALIN® LN,一种结合增效醚和 alpha-氯氰菊酯的网;(3)Interceptor® G2 LN,一种含有氯氟氰菊酯和 alpha-氯氰菊酯的网,两种杀虫剂具有不同的作用机制,对流行病学和昆虫学结果的疗效。将确定并绘制 33 个平均每个村庄有 200 户家庭的村庄图谱,并以 1:1:1 的比例随机分组。按照国家指南,在一个中心点分发蚊帐,每两人发放 1 顶。该试验的主要结局是每个群集中每 50 名 6 个月至 10 岁的儿童的疟疾病例(通过快速诊断测试(RDT)确诊)的发病率,随访 12 个月(主动病例检测)。次要结局是在干预后 6 和 12 个月,在研究人群中通过 RDT 检测的疟疾感染的横断面社区患病率(每个群集中随机选择 50 人)、蚊虫密度、昆虫接种率(EIR)以及在每个治疗臂的 3 个哨点村庄中,在基线和干预后 12 个月时的表型和基因型杀虫剂抗性。
除了为下一代 LLIN 提供更多证据外,这项研究还将为西非法国家提供第一个关于增效醚-拟除虫菊酯网的证据。这可能会进一步为世卫组织关于实用型增效醚-拟除虫菊酯网的建议提供信息。
ClinicalTrials.gov NCT05796193。2023 年 4 月 3 日注册。